ArticleScientific reports2026
An advanced hybrid deep learning framework for high-precision brain tumor detection and classification in MRI scans.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early and accurate identification of brain tumors from magnetic resonance imaging (MRI) is essential for timely clinical intervention; however, manual interpretation remains time-consuming and dependent on expert analysis. The study proposes MultiAttenNet, a hybrid deep learning framework that integrates multi-scale convolutional neural networks (CNNs) for hierarchical feature extraction and Transformer-based attention mechanisms for global contextual learning, within a semi-supervised learning paradigm. The multi-scale feature extraction improves robustness in detecting tumors of varying sizes and irregular structures, while the adaptive attention module dynamically emphasizes diagnostically relevant regions to enhance localization and reduce false positives. A consistency-based semi-supervised learning scheme enables effective training using limited labeled data alongside unlabeled samples, improving generalization across diverse clinical scenarios. The framework is evaluated using the BraTS 2023 for glioma segmentation and publicly available datasets such as the Figshare Brain Tumor Dataset for multi-class tumor classification (glioma, meningioma, and pituitary tumors), MultiAttenNet achieves accuracy, sensitivity, specificity, and false-positive rates of 98.4, 96.8, 99.2 and 1.3%, respectively, outperforming existing state-of-the-art approaches. The proposed framework provides a scalable and efficient solution for real-time clinical brain tumor diagnosis and supports reliable automated decision-making in neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.